Clinical Trials Logo

Bone Marrow Diseases clinical trials

View clinical trials related to Bone Marrow Diseases.

Filter by:

NCT ID: NCT04173923 Completed - Cervical Myelopathy Clinical Trials

Long Term Follow-up of Cervical Myelopathy Inpatients Treated With Integrated Complementary and Alternative Medicine

Start date: November 20, 2018
Phase:
Study type: Observational [Patient Registry]

Model of this study is a combined both retrospective chart review and follow up survey. Data of 4 hospitals will be used to find out the efficacy of conservative treatment in cervical myelopathy.

NCT ID: NCT04167605 Recruiting - Bone Metastases Clinical Trials

Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases

BC-BOMET
Start date: January 13, 2020
Phase:
Study type: Observational

Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called "Skeletal-related Events" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at "high risk" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer.

NCT ID: NCT04159376 Not yet recruiting - Bone Metastases Clinical Trials

Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases

Start date: December 25, 2019
Phase: N/A
Study type: Interventional

The great promise of PET/MR for assessment of skeletal metastatic involvement is derived from the extensive experience with stand- alone MR, but initial data on the use of PET/MR for assessment of bone pathology indicate that PET/MR introduces unique issues that should be addressed when determining its role in this clinical scenario. In this study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed. The main goal of the study is to asses the accuracy of PET/MR in detection and monitoring response of bone metastases.

NCT ID: NCT04141306 Not yet recruiting - Thyroid Cancer Clinical Trials

Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

Start date: November 2019
Phase:
Study type: Observational

Bone radioiodine (RAI) uptake without structural abnormality in thyroid cancer (TC) patients may be related to false positive or to microscopic foci of metastatic tissue. In such cases, outcome is reported to be excellent. Indeed, Robenshtok et al. reported a serie of patients with RAI-avid bone metastases of TC without structural abnormality on imaging studies who have more favorable long-term prognosis than those harbouring structurally visible bone metastases and do not undergo skeletal-related complications. The investigators report the case of Mrs D., who had been operated for a pathologic tumor stage 3: pT3(m) poorly differentiated TC at the age of 43. The first post-therapeutic whole body scan revealed 3 foci of bone uptake (right clavicle, L2, L3). The elevated level of thyroglobulin (157ng/mL) favoured the hypothesis of bone metastases despite the absence of any structural lesion on CT and MRI. She received 7 courses of radioiodine therapy. The right clavicle RAI uptake persisted, and subsequent CT disclosed an osteolytic lesion which was treated by radiofrequency and external beam radiation. Twenty-five years after the diagnosis, she has a persistent morphological disease with a 30x8mm progressive lesion on the right clavicle, for which surgery is planned. The aim of the present study is to describe the natural history and evolution of radioiodine avid bone metastases from thyroid cancer without structural abnormalities and to identify prognosis factors.

NCT ID: NCT04109937 Withdrawn - Bone Metastases Clinical Trials

External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial

EXPLORE
Start date: October 2020
Phase: N/A
Study type: Interventional

The objective of the present study is to evaluate the effectiveness of post-operative radiation therapy in lower extremity bone metastases. This trial will compare the health outcomes of patients receiving radiation therapy after Orthopaedic surgery to patients who will not receive radiation therapy post-surgery. The primary objective of the study is to compare the need for a subsequent surgery at the same treatment site within 12 months of the initial surgery. Additionally, the need for radiation or re-irradiation, functional status, performance status, pain scores, radiologically detected local disease progression, and overall length of survival will be compared at clinical endpoints for the two study arms. It is hypothesized that those randomized to receive post-operative radiation therapy will less likely need a subsequent surgery within the 12 months after the primary surgical intervention. This may optimize the quality of life for this patient population.

NCT ID: NCT04080271 Completed - Bone Metastases Clinical Trials

Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.

PET/CT
Start date: November 1, 2019
Phase:
Study type: Observational

The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.

NCT ID: NCT04063254 Not yet recruiting - Bone Metastases Clinical Trials

A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases

Start date: August 30, 2019
Phase: Phase 2
Study type: Interventional

In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal technique for bone metastases. Our findings should be able to provide evidence-based recommendation to support the utilization of single fraction radiotherapy for value-based oncology practice.

NCT ID: NCT04004819 Recruiting - Clinical trials for HTLV-1-associated Myelopathy

Rituximab for HTLV-1-associated Myelopathy

Start date: August 15, 2019
Phase: Phase 2
Study type: Interventional

Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.

NCT ID: NCT03986593 Terminated - Clinical trials for Neuroendocrine Tumors

Cryoablation of Bone Metastases From Endocrine Tumors

Start date: September 26, 2019
Phase: N/A
Study type: Interventional

This study will evaluate the clinical response and safety of cone beam computed-tomography guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine tumors in 30 patients.

NCT ID: NCT03979118 Completed - Advanced Cancer Clinical Trials

Exercise Prescription in Patients With Bone Metastases

Ex-Met
Start date: October 15, 2019
Phase:
Study type: Observational

Cancer which has spread to the bone, causing bone metastases (bone tumours) can weaken bone health and increase risk of fractures (breaks). Consequently, patients can be unsure whether to exercise and health professionals can be unsure what exercise advice is suitable. Despite this, it is well known that exercise improves quality-of-life for patients with bone metastases and therefore it is important that exercise is prescribed to these patients. This study aims to increase understanding of the link between daily exercise and risk of fracture in patients with bone metastases.